Metabonomics

Content related to Metabonomics:

 

Evaluating drug safety

By Donald G. Robertson, Metabonomics Evaluation Group, Departments of Worldwide Safety Sciences and Michael D. Reily, Discovery Technologies, Pfizer Global Research and Development

Send this to a friend